Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar… - Nature reviews Clinical …, 2018 - nature.com
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
D Fukumura, J Kloepper, Z Amoozgar… - Nature reviews …, 2018 - folia.unifr.ch
English Immunotherapy has emerged as a major therapeutic modality in oncology.
Currently, however, the majority of patients with cancer do not derive benefit from these …
Currently, however, the majority of patients with cancer do not derive benefit from these …
[PDF][PDF] Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar, DG Duda… - researchgate.net
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
D Fukumura, J Kloepper, Z Amoozgar… - Nature reviews …, 2018 - europepmc.org
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …
[PDF][PDF] Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar, DG Duda… - academia.edu
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
D Fukumura, J Kloepper, Z Amoozgar, DG Duda… - Nature reviews. Clinical …, 2018 - sonar.ch
English Immunotherapy has emerged as a major therapeutic modality in oncology.
Currently, however, the majority of patients with cancer do not derive benefit from these …
Currently, however, the majority of patients with cancer do not derive benefit from these …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper… - Nature reviews …, 2018 - pubmed.ncbi.nlm.nih.gov
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …
[引用][C] Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar… - Nature Reviews …, 2018 - cir.nii.ac.jp
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar… - Nature Reviews …, 2018 - hero.epa.gov
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar… - Nature Reviews …, 2018 - go.gale.com
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …